Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sonoma Pharmaceuticals (SNOA) Revenue (2016 - 2025)

Sonoma Pharmaceuticals has reported Revenue over the past 16 years, most recently at $4.3 million for Q4 2025.

  • For Q4 2025, Revenue rose 22.03% year-over-year to $4.3 million; the TTM value through Dec 2025 reached $17.7 million, up 26.83%, while the annual FY2025 figure was $14.3 million, 12.19% up from the prior year.
  • Revenue for Q4 2025 was $4.3 million at Sonoma Pharmaceuticals, down from $5.6 million in the prior quarter.
  • Over five years, Revenue peaked at $5.6 million in Q3 2025 and troughed at $2.2 million in Q1 2021.
  • A 5-year average of $3.5 million and a median of $3.4 million in 2023 define the central range for Revenue.
  • Biggest five-year swings in Revenue: crashed 49.98% in 2021 and later skyrocketed 56.58% in 2025.
  • Year by year, Revenue stood at $2.9 million in 2021, then grew by 1.45% to $2.9 million in 2022, then rose by 6.59% to $3.1 million in 2023, then grew by 13.58% to $3.6 million in 2024, then rose by 22.03% to $4.3 million in 2025.
  • Business Quant data shows Revenue for SNOA at $4.3 million in Q4 2025, $5.6 million in Q3 2025, and $4.0 million in Q2 2025.